Hims & Hers Q2 revenue beat offset by wider-than-expected loss
Hims & Hers Health reported Q2 revenue of $753.2 million, up 38% year over year and above analysts’ ~$699 million estimate. The company posted a wider-than-expected loss of $0.37 per share, citing restructuring charges tied to its branded GLP-1 shift. Subscribers rose 19% to nearly 2.9 million. It raised FY2026 revenue guidance to $3.1-$3.3 billion.
How this was made
The 30-second read
Why it matters
Q2 results combine a revenue beat and raised full-year outlook with a wider-than-expected loss, implying near-term margin pressure but improving top-line momentum.
Market read
Traders can update models using the raised 2026 revenue range and the Q3 revenue and adjusted EBITDA margin guidance, while monitoring restructuring-driven profitability risk.
What to watch
International growth is described as strengthened by the Eucalyptus acquisition, so investors may scrutinize integration costs and whether subscriber growth translates into sustainable adjusted EBITDA margins.
Background
Hims & Hers is shifting toward branded GLP-1 weight-loss options and is restructuring as part of that transition.
Ticker impact
Hims & Hers reported Q2 revenue of $753.2M, beating expectations, but widened its loss to $0.37 per share and raised full-year guidance.
Near-term volatility likely, with traders weighing raised revenue outlook against margin pressure from restructuring and the wider loss.
Revenue beat and guidance raise can support the stock, but the loss miss and restructuring charges suggest near-term profitability headwinds.
Market effects
Reinforces that branded GLP-1 weight-loss repositioning can drive restructuring costs even as growth re-accelerates for telehealth/consumer health platforms.
No specific regional shock beyond stated domestic and international growth acceleration.
International growth acceleration (Eucalyptus acquisition close) may support broader investor appetite for scaled consumer health platforms.
Counterpoint
The revenue beat may be partly offset by one-time restructuring charges, so the market could refocus on normalized profitability rather than the GAAP loss.
Key entities
- companyHims & Hers Health
Telehealth and consumer health platform reporting Q2 results and updated 2026 and Q3 guidance.
- executiveYemi Okupe
CFO quoted on growth re-acceleration and international expansion.
- executiveAndrew Dudum
CEO quoted on rebuilding the consumer health experience with a doctor-led AI clinical engine.
